Summit Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
22.3%projected annual EPS growth
Analyst Coverage
13analysts covering
FY Revenue (est.)
$2.9Mnext fiscal year
FY EPS (est.)
-$0.86next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| FDA PDUFA Action Date for Ivonescimab BLA | 14 Nov 2026 |
Monitoring Framework
Key Performance Indicators
HARMONi-3 Phase III Squamous Cohort Patient Screening Quarterly600.0Target: 600 (Completed ahead of schedule)
Cash and Cash Equivalents Quarterly713.4MTarget: Maintain sufficient runway for clinical trials
Ongoing and Planned Randomized Phase III Trials Annually15.0
Watch Items
- FDA BLA Review for Ivonescimab in EGFR-mutant NSCLCTrigger: PDUFA DateAction: Monitor FDA decision on or around November 14, 2026
- HARMONi-3 Final Progression-Free Survival (PFS) AnalysisTrigger: Data Cut-off / Final AnalysisAction: Evaluate final PFS data in H2 2026 following the interim PFS analysis update
- Capital Runway and Dilution RiskTrigger: Cash Burn Rate vs. Capital RaisesAction: Track cash position and potential future equity offerings to fund late-stage trials
Research as of 2 Sep 2026